Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=461 Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 28 — -0.96; -0.22 Percentage of HbA1c — p=<0.001
N/A N=20 Discrete Versus Rhythmic Gait Training
Stroke · Cerebral Vascular Disorders
Primary: Functional Ambulation Scale (FAC) — 1; 0 units on a scale
N/A N=300 Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment
Opiate Dependence
Primary: Number of Participants With Opiate Positive Urine Tests — 89; 90 Participants — p=0.92
N/A N=82 Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing
Breast Cancer
Primary: Compare the Diagnostic Accuracy of 8 mCi Molecular Breast Imaging (MBI) With 4 mCi MBI. — 30; 29 cancers detected
Phase 3 N=302 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN…
Phase 2 N=189 Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
Atrial Fibrillation · Atrial Flutter
Primary: Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing — 7.870; 10.517 ng/mL
N/A N=12 Treatment of Executive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Clinical Global Impression of Change-Clinician Rated Score (CGIC-C) — 3; 6; 1; 2 Participants
N/A N=12 Exercise Program in Women With Metabolic Syndrome
Metabolic Syndrome
Primary: Maximal Oxygen Uptake — 18.3; 15.8; 18.6; 14.4 ml/kg/min
Phase 2 N=3 Levetiracetam for the Treatment of Alcohol Dependence and Anxiety
Alcoholism · Generalized Anxiety Disorder · Panic Disorder
Primary: Participants Who Reported Reductions in Alcohol Consumption — 3 Participants
Phase 2 N=32 Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
Phase 3 N=141 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
Chronic Hepatitis C · Hepatitis C Virus · HCV
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100; 95.5; 86.4; 88.6 percentage of participants
Phase 4 N=525 Reducing Total Cardiovascular Risk in an Urban Community
Cardiovascular Diseases · Heart Diseases · Coronary Disease
Primary: Low-density Lipoprotein Cholesterol — 100.1; 110.6 mg/dL — p=<0.001
Phase 3 N=42 Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
Post-surgical Cystoid Macular Edema (PSCME)
Primary: Mean Change in Best-Corrected Visual Acuity at Week 12 From Baseline — 10.6; 7.8; 13.1; 9.4 letters
Phase 3 N=179 Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
Diabetes Mellitus, Type 1
Primary: Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12 — -0.14; -0.23 nanomoles per…